Carregant...

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common adult leukemia, with an overall poor prognosis. New agents targeting various receptors may improve treatment outcomes and overall survival. FMS-like tyrosine kinase 3 (FLT3) is a targetable mutation occurring in one third of AML patients. It contribute...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Adv Pract Oncol
Autors principals: Marjoncu, Dennis, Andrick, Benjamin
Format: Artigo
Idioma:Inglês
Publicat: Harborside Press LLC 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7517771/
https://ncbi.nlm.nih.gov/pubmed/33542854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.1.7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!